[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mediastinitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mediastinitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100631955","phase-4-innovative-sternal-closure-techniques-evaluating-stratafix-and-dermabond-for-reduced-complications-in-cabg-patients-100631955",false,"NCT07507409","Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients","Inclusion Criteria:\n\n\\- Patients aged 18 years and older undergoing CABG surgery.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the trial.\n* Patients who do not read or speak English.\n* Patient with allergy to surgical adhesives or sutures","ALL","18 Years",{"count":18,"type":19},401,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The goal of this clinical trial is to learn if a new method of closing the breastbone after heart bypass surgery can improve healing and reduce complications in adults undergoing coronary artery bypass graft (CABG) surgery.\n\nThe main questions it aims to answer are:\n\nDoes this new closure method reduce infections and wound reopening? Does it improve healing, recovery, and overall patient outcomes?\n\nResearchers will compare patients who receive the new closure method to past patients who received the standard method to see if outcomes are better.\n\nParticipants will:\n\nReceive the new closure method during their surgery (as part of standard care) Be followed during their normal recovery up to their 6-week follow-up visit Complete a short quality-of-life questionnaire (about 10 minutes) Have their recovery assessed, including healing, complications, and hospital use\n\nResearchers will also look at quality of life, heart complications, hospital readmissions, antibiotic use, scar appearance, and overall costs to understand the full impact of the new method.",[25,26,27,28],"Cardiovascular Disease","Surgical Site Infection","Superficial Sternal Wound Infection","Mediastinitis",[30,31,32,33,34],"STRATAFIX","DERMABOND","Sternal Closure","Suture","CABG","NOT_YET_RECRUITING","2026-04-07",{"date":38,"type":39},"2026-04-13","ACTUAL",{"date":41,"type":19},"2026-05-01",{"date":43,"type":19},"2028-05-01",{"name":45,"class":46},"Unity Health Toronto","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100625733","delafloxacin-plasma-and-tissue-concentration-in-patients-with-skin-soft-tissue-and-bone-and-joint-infections-100625733","NCT07426471","Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.","Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections: a Prospective Mono-center Observational Pharmacological Study.","DELA-PLAT","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study, and to be concurrently enrolled in the Institutional Infectious Disease Biobank (INDI-REBIO, NCT06418048)\n* \\>18 years-old\n* eGFR of \\> 80 mL\u002Fmin\u002F1,73m2\n* Receiving delafloxacin 300mg q12h IV according to treating physician's choice and good clinical practice or available guidelines with bacterial skin and skin structure infection and with\n\n  1. post-sternotomy wound infection and\u002For mediastinitis undergoing surgical debridement\n  2. prosthetic joint infections undergoing surgical debridement or prosthetic joint removal (either one-stage, e.g. when the Infected prosthesis is removed and a new one is implanted in the same surgery, or two-stage, when the Infected prosthesis is removed, followed by a period of antibiotics, then a new prosthesis is implanted in a second surgery).\n\nExclusion criteria:\n\n* Patients who received other quinolones (oral or IV) in the week preceding the sample collection\n* Patients who decline or are unwilling to participate in serial blood draws at all five designated time points.\n* Pregnant or lactating women",{"count":56,"type":19},20,"1 Day","OBSERVATIONAL","The goal of this observational study is to measure how well the antibiotic delafloxacin penetrates into the blood and various body tissues in adult patients over 18 years old. Specifically, this study focuses on patients who are receiving the drug to treat bacterial infections and are undergoing surgery for post-sternotomy wound infections, mediastinitis, or infected prosthetic joints .\n\nThe main questions it aims to answer are:\n\n* What is the concentration of delafloxacin in the blood plasma?\n* What is the concentration of delafloxacin in different body tissues, including soft tissue, tissue around a prosthetic implant, joint fluid (synovial fluid), and bone ?\n* How does the concentration of the drug in the blood compare to its concentration in the tissues?\n* Do patient factors such as age, body weight, and kidney function affect the drug's levels in the body?\n\nParticipants will:\n\n* Continue to receive delafloxacin (300mg intravenously every 12 hours) as prescribed by their treating physician for their infection.\n* Allow researchers to draw 5 peripheral blood samples (about 10 mL total) at specific times (15 minutes, 1 hour, 3 hours, 5-7 hours, and 11 hours) after the end of a single delafloxacin infusion.\n* Allow researchers to collect small amounts of tissue and joint fluid for testing during their already planned surgical procedure.",[61,28,62,63],"Soft Tissue Infections","Osteomyelitis\u002FSeptic Arthritis","Prosthetic Joint Infection","2026-02-20",{"date":66,"type":39},"2026-02-23",{"date":68,"type":19},"2026-04-01",{"date":70,"type":19},"2027-01-31",{"name":72,"class":46},"IRCCS San Raffaele"]